Brolucizumab, a humanized anti-vascular endothelial growth factor A (VEGF-A) scFv to treat neovascular age-related macular degeneration (nAMD), has demonstrated a greater durability and effectiveness in a 12-week regimen compared to conventional treatments, which depended on directly injecting anti-VEGF-A solutions.57 Here, VEGFA is linked to age-related macular degeneration.